How does Kenvue make money?

Kenvue Inc. – Business Breakdown

The Essentials

Kenvue Inc. is a consumer health company organized around three operating segments: Self Care, Skin Health and Beauty, and Essential Health. Its portfolio spans widely recognized brands across cough/cold/allergy, pain care, digestive health, smoking cessation, eye care, face/body care, hair, sun care, oral care, baby care, women’s health, and wound care. The company was incorporated in 2022, headquartered in Summit, New Jersey, and became fully independent in 2023 following its spin-off from J&J.

From a business-quality perspective, Kenvue’s industrial significance lies in the breadth of its branded consumer health platform and the scale of its distribution footprint across the U.S. and international markets. However, the filings also indicate that the company is operating through a period of strategic transition, with restructuring activity, leadership change, and a pending merger with Kimberly-Clark shaping the near-term profile.

Business Model & Revenue Drivers

Kenvue generates value through branded consumer health products sold across multiple end markets. The filings identify three core segments:

• Self Care

  • Includes cough/cold/allergy, pain care, digestive health, smoking cessation, and eye care.
  • Brands cited include Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSL, Rhinocort, Calpol, and Zyrtec.
  • This segment appears central to the company’s consumer franchise and brand equity.

• Skin Health and Beauty

  • Covers face/body care, hair, and sun care.
  • Brands cited include Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX.
  • The filings note an impairment related to Dr.Ci:Labo, which suggests pressure in part of the portfolio.

• Essential Health

  • Includes oral care, baby care, women’s health, and wound care.
  • Brands cited include Listerine, Johnson’s, Band-Aid, Stayfree, o.b., Carefree, and Desitin.
  • This segment provides diversification across recurring consumer health categories.

On geography, the filings indicate that international operations are a primary revenue driver, with meaningful exposure across Canada, China, Japan, Singapore, Europe, India, and Latin America. The U.S. remains important as well, with income before taxes of $585 million, representing 29% of $1.999 billion total in the referenced disclosure. For Q3 2025, Kenvue reported net sales of $3.764 billion, down 3.5% year over year, with organic growth of -4.4%, underscoring a softer operating backdrop.

Strategic Edge & Market Positioning

Economic Moat:
Based strictly on the filings, no durable structural moat is clearly evidenced. The company’s brands are valuable and recognizable, but the source does not show high switching costs, network effects, proprietary technology, or cost advantages that would constitute a strong economic moat. The portfolio appears to derive strength from consumer familiarity, marketing reach, and shelf presence rather than from entrenched structural barriers.

Execution Advantage:
Kenvue does appear to have an execution-based advantage through its portfolio of established brands and broad category coverage. These assets can support pricing power, distribution leverage, and brand-led demand generation. That said, the filings also point to vulnerabilities: organic volume pressure, tariff exposure, foreign exchange losses, and an impairment in Skin Health. In other words, the company’s positioning is better described as a brand-driven operating platform than a structurally protected franchise.

The merger fairness opinion comparables referenced in the profile — P&G, Unilever, and Reckitt Benckiser — reinforce that Kenvue is being evaluated within a premium branded consumer health peer set, but the filings do not support a conclusion that it possesses comparable structural resilience.

Outlook & Innovation Pipeline

The next three years appear to be defined less by breakthrough innovation and more by portfolio optimization, cost discipline, and strategic repositioning.

Key elements of the outlook include:

• 2024 Multi-Year Restructuring Initiative

  • Focused on IT infrastructure and cost optimization.
  • Includes employee severance, IT/project costs, contract terminations, and asset-related actions.
  • This suggests a multi-year effort to improve operating efficiency and resource allocation.

• Pending merger with Kimberly-Clark

  • Announced in November 2025, with Kenvue shareholders expected to receive 0.5965 K-C shares plus $3.50 in cash per share.
  • The transaction implies a major strategic reset, with a projected ownership split of approximately 46% Kenvue / 54% K-C.
  • The merger could materially reshape capital allocation, integration priorities, and the company’s medium-term operating roadmap.

• Leadership transition

  • Kirk L. Perry was appointed permanent CEO in November 2025.
  • Amit Banati is scheduled to step down as CFO in May 2026.
  • This indicates a period of governance and execution transition at a critical juncture.

• Innovation and R&D

  • The filings do not identify a robust proprietary innovation pipeline, patent-led growth engine, or differentiated technology platform.
  • A new R&D building in Summit, New Jersey is under construction and expected to complete in 2026, but the source does not quantify any associated product pipeline or technological advantage.

Overall, Kenvue’s forward strategy appears centered on operational simplification, cost takeout, and strategic combination, rather than on a clearly articulated innovation-led growth cycle.